Here's the unpopular take: restraint, not speed, may be the smarter strategy for insurers scrambling to add obesity medications to their formularies.
We're watching a familiar script play out in real time. A new class of drugs gains cultural momentum. Insurers face pressure, both consumer and competitive, to cover them quickly. Coverage expands rapidly. Then, somewhere between months six and eighteen, the unintended consequences emerge: formulary churn, prior authorization bottlenecks, unexpected cost trajectories, or coverage decisions that looked prudent in year one but feel reckless in year three.
The current rush around GLP-1 receptor agonists for weight loss feels different, the industry insists. This time we'll be thoughtful. This time we've learned from past mistakes. Maybe. But the structural incentives pushing toward fast coverage haven't changed, and neither has human nature.
Let's be clear about what's happening. Employers and health plans are under genuine pressure. Patients want access. Pharmaceutical manufacturers are marketing aggressively. The political environment now includes conversations about obesity coverage that would have been unthinkable five years ago. When major pharmacy benefit managers and insurers move to include these medications, it's not happening in a vacuum. It's happening because inaction carries its own reputational and competitive costs.
But speed has a cost too, one that often gets ignored until it's too late to manage gracefully.
These drugs are expensive. Really expensive. The per-patient annual cost can run into five or even six figures for some formulations, depending on dosing and duration of therapy. We don't yet have reliable long-term actuarial data on how many patients will use them, for how long, or what the real-world clinical outcomes will look like when these medications are deployed at scale across diverse populations with different health profiles and comorbidities.
That's not a complaint about the drugs themselves. It's a structural reality. We're still learning how these medications perform outside clinical trials, in actual insurance populations, with actual adherence patterns and real-world side effect management.
When insurers move quickly, they're essentially betting that early coverage decisions will hold up under scrutiny. Sometimes that works out. Sometimes it doesn't. The insurance industry has a reasonably long history of having to walk back coverage policies that seemed straightforward at the time but created problems—cost spirals, access disparities, administrative nightmares—once implemented at scale.
A more measured approach would look different. It might mean starting with more restrictive coverage criteria, then expanding based on real-world evidence. It might mean stronger prior authorization frameworks, at least initially, rather than rushing toward open access. It might mean building in explicit review windows where coverage decisions get re-examined as actual claims data accumulates.
This isn't about denying people access to medications that might help them. It's about acknowledging that insurance systems work better when major coverage decisions have time to stabilize before they're cemented into place.
The counterargument is obvious: patients need these medications now, not after a two-year evidence-gathering period. Fair point. But the question isn't binary. The question is what pace of expansion actually serves patients better over a five-year horizon, not just the next five months.
Restraint sounds boring. It's not exciting to tell investors, employers, or patients that you're taking a measured approach. Speed gets headlines and market share. But insurance, at its best, is supposed to be a tool for managing long-term risk responsibly, not a mechanism for chasing the next big trend as fast as possible.
The smart money might be betting that the insurers who move deliberately now will look smarter in 2028 than the ones who committed to full-scale coverage without fully understanding the implications.